Aurobindo Pharma, a leading generic drug manufacturer, has launched a six-month post-graduation certification in leadership (CLP) program at the Institute of Management Technology, Hyderabad (IMT Hyderabad). The program, introduced through Aurobindo’s wholly-owned subsidiary Apitoria, aims to transform promising professionals into dynamic leaders by equipping them with essential skills in managing themselves, teams, business, and change.
The CLP program consists of 13 days of classroom sessions, spread across six modules, which will be delivered through a blend of traditional and modern teaching methods. The program is designed to be immersive and practice-oriented, providing participants with hands-on experience and real-world applications. The curriculum is tailored to help middle managers develop the skills and confidence needed to take on larger responsibilities and drive business growth.
According to U.N.B. Raju, Senior Vice President of Corporate HR at Aurobindo Pharma, the introduction of the CLP program is a testament to the company’s commitment to nurturing talent and enabling the growth of middle management. “It is an important step in grooming our middle managers to take on larger responsibilities with confidence and agility,” Raju said. The program is expected to play a critical role in connecting strategy with execution, driving business success, and fostering a culture of leadership and innovation within the organization.
The launch of the CLP program is a strategic investment in the development of Aurobindo Pharma’s human capital, recognizing the critical role that middle managers play in driving business growth and success. By partnering with IMT Hyderabad, Aurobindo Pharma aims to provide its employees with access to world-class education and training, empowering them to excel in their roles and contribute to the company’s continued success. With the CLP program, Aurobindo Pharma is poised to develop a pipeline of talented leaders who can drive business growth, innovation, and excellence in the pharmaceutical industry.